HHS grants blanket conflict waivers to every U.S. Preventive Services Task Force member

Federal health officials have issued blanket conflict-of-interest waivers to every member of the U.S. Preventive Services Task Force, the panel whose grades on screening and preventive care shape what many insurers must cover without patient cost-sharing. Documents signed by a top official in Health and Human Services Secretary Robert F. Kennedy Jr.’s department allow members to serve even when they have financial stakes in services the panel may evaluate. The waivers cover the full roster, including newer appointees whose disclosed interests are described as more extensive than those of longer-serving members.

According to the filings as described, this is not a single isolated disclosure. In two cases, members own private medical practices that could gain business if the task force recommends particular kinds of care. Other waived interests include stock in pharmaceutical and medical-device companies and jobs at public research universities that themselves deliver care. A university salary is not the same exposure as equity in a product under review, but a blanket waiver treats them as one permission rather than requiring recusal when a recommendation touches a holding or a practice’s revenue.

That distinction matters because this panel is not merely advisory. Under the Affordable Care Act, services it rates A or B generally must be covered by most private plans with no copay, reaching tens of millions of people and shifting spending toward particular tests and treatments. Kennedy has treated corporate influence in medicine as a central charge. Waiving every member, instead of requiring recusal when a recommendation touches a practice or a holding, sets aside the usual safeguard where it would bind. The filings document permission to serve. They do not show that any grade was cast for personal gain.

What comes next is whether HHS publishes the waivers, names the interests specifically enough for outside review, and states a recusal rule for votes that touch a practice, device, or drug holding. Insurers and Congress will watch the next A or B grades, because those grades can become coverage mandates. The evidence in hand is documentary, not experimental: it can show conflicts were waived across the panel, including practice ownership and industry equity. It cannot show how often recusal would have been required, or whether any recommendation changed.